# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elisabeth of Austria (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI030-SYN
- Date: 2026-04-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Adelheid Marchetti-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Twelve-week review of anorexia nervosa, mood and sertraline. **S**

## History of present illness

Empress Elisabeth returns eight weeks after her four-week review. She has taken sertraline 50 mg for six weeks; the nurse check two weeks after starting found only mild nausea, which passed. She has kept to the meal plan with the dietitian's help, including by video during a two-week journey, and attends CBT-E weekly. She walks about an hour a day and has not used the gymnastics apparatus. She feels warmer and steadier. Her mood is a little better; she has had no thoughts of death for three weeks. She still dislikes seeing her weight but tolerates the open weighing. **S**

| Element | Detail |
|---|---|
| Sertraline | 50 mg for six weeks; early nausea passed |
| Treatment | Weekly CBT-E; dietitian by video while travelling |
| Exercise | About an hour of walking a day |
| Safety | No thoughts of death for three weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Warmer; more energy |
| Cardiovascular | Negative | No swelling, palpitations or dizziness |
| Gastrointestinal | Negative | Fullness after meals much less |
| Psychiatric | Positive | Mood a little better; PHQ-9 10 |

4 systems reviewed. **S**

## Current medications

- Cholecalciferol 50 microgram (2,000 IU) capsule, one by mouth daily **S**
- Calcium carbonate 1,250 mg (500 mg elemental calcium) tablet, one by mouth daily with a meal **S**
- Sertraline 50 mg tablet, one by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 104/66 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.4 °C; oxygen saturation 98% on room air; weight 52 kg; BMI 17.6 kg/m². All vital signs are synthetic.

Hemoglobin: 12.4 g/dL; White cell count: 4.4 10*3/uL; Sodium: 137 mmol/L; Potassium: 4 mmol/L; Magnesium: 2 mg/dL; Phosphate: 3.4 mg/dL; ALT: 30 U/L; PHQ-9: 10. All results are synthetic.

## Change since baseline

- Hemoglobin: 11.2 g/dL (low) at baseline, 12.4 g/dL at this visit **S**
- White cell count: 3.4 10*3/uL (low) at baseline, 4.4 10*3/uL at this visit **S**
- Sodium: 136 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 3.6 mmol/L at baseline, 4 mmol/L at this visit **S**
- Magnesium: 1.8 mg/dL at baseline, 2 mg/dL at this visit **S**
- Phosphate: 3 mg/dL at baseline, 3.4 mg/dL at this visit **S**
- ALT: 52 U/L (high) at baseline, 30 U/L at this visit **S**
- PHQ-9: 16 at baseline, 10 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin; weight 52.0 kg, BMI 17.6; temperature 36.4 C |
| Cardiovascular | Seated blood pressure 104/66, pulse 60; no orthostatic change; no edema |
| Psychiatric | Calmer; mood mildly low; no intent or plan to harm herself |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Anorexia nervosa, restricting type, improving** (F50.011). Weight 52.0 kg, BMI 17.6, gaining about 0.3 kg a week over the past eight weeks, slower than the target of 0.5 to 1 kg a week. Pulse 60 and no orthostatic change; edema gone. Potassium 4.0 mmol/L, phosphate 3.4 mg/dL, magnesium 2.0 mg/dL; hemoglobin 12.4 g/dL, white cells 4.4 x10^3/uL and ALT 30 U/L now normal. **S**
   - The dietitian will add about 300 kcal a day.
   - Continue CBT-E.
   - Walks of up to an hour a day; the team will review gentle stretching at the next visit.
2. **Recurrent depression with persistent grief, improving** (F33.1). PHQ-9 10, from 16; not yet a 50 percent response, but improving after six weeks of sertraline 50 mg. Sodium 137 mmol/L on sertraline. **S**
   - Continue sertraline 50 mg; increase if the PHQ-9 is not lower at the next review.
   - Safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.
3. **Low bone mass** (M85.80). On calcium and vitamin D. **S**
   - 25-hydroxyvitamin D at the next review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Weight and BMI (open weighing in the consulting room) | Weekly at first, then every visit | Completed today | 52.0 kg, BMI 17.6; up 2.4 kg in eight weeks |
| Examination | Orthostatic pulse and blood pressure, and temperature | Every visit | Completed today | Pulse 60, blood pressure 104/66, no orthostatic change; temperature 36.4 C |
| Laboratory | Sodium, potassium, phosphate, magnesium and glucose | Baseline; three to four days after nutrition starts; weekly for the first weeks; then at each visit while underweight | Completed today | Sodium 137, potassium 4.0 mmol/L, phosphate 3.4 mg/dL, magnesium 2.0 mg/dL |
| Laboratory | Blood count and liver enzymes | Baseline; repeat when abnormal | Completed today | Hemoglobin 12.4 g/dL, white cells 4.4 x10^3/uL, ALT 30 U/L: normal |
| Imaging | ECG for bradycardia and QTc | Baseline; repeat with abnormal electrolytes and before QT-prolonging drugs | Not indicated | QTc 436 ms before sertraline; pulse and electrolytes normal; no new QT-prolonging drug |
| Examination | Refeeding edema and signs of heart failure | Every visit | Completed today | No edema |
| Self-management | Exercise and compulsive activity | Every visit | Completed today | About an hour of walking a day; no gymnastics |
| Self-management | Multidisciplinary treatment: CBT-E attendance, dietitian, psychiatry | Weekly therapy; dietitian every two weeks | Completed today | Weekly CBT-E; dietitian in person and by video |
| Survey | PHQ-9 | At least monthly during acute treatment | Completed today | 10, from 16 at intake |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit | Completed today | No thoughts of death for three weeks; PHQ-9 item 9 scored 0. Safety plan reviewed |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Completed today | Done by nurse telephone call two weeks after starting: mild nausea only; no activation or bleeding |
| Medication safety | Adherence and adverse-effect review; sodium on an SSRI | Every visit | Completed today | No missed doses; sodium 137 mmol/L |
| Laboratory | 25-hydroxyvitamin D after repletion | About three months after starting, then yearly | Due | Due at the next review |

## Goal progress

- Medically stable for outpatient care: resting pulse 50 or more, no orthostatic dizziness, and normal potassium, phosphate, magnesium and glucose. Outcome by 2026-03-03: Pulse 56, orthostatic changes resolved, electrolytes and glucose normal at four weeks. **S**
- Weight gain of about 0.5 to 1 kg a week toward a body mass index of at least 18.5. In progress; target 2026-08-31. **S**
- Depression response (PHQ-9 down by at least 50 percent) by six months. In progress; target 2026-06-30. **S**
- Exercise reduced to walks of an hour or less a day while weight is restored, with no gymnastics until the team agrees. Outcome by 2026-04-28: Walks of about an hour a day; gymnastics stopped. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders, Fourth Edition (2023), American Psychiatric Association (American Journal of Psychiatry 2023;180(2):167-171)
- Medical Management of Restrictive Eating Disorders in Adolescents and Young Adults (position paper) (2022), Society for Adolescent Health and Medicine (J Adolesc Health 2022;71(5):648-654)
- Eating Disorders: A Guide to Medical Care (AED Medical Care Standards Guide), 4th edition (2021), Academy for Eating Disorders
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders and osteoporosis monographs (2026), Aether Forge
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Review in about nine weeks. **S**
- Next scheduled visit 2026-06-30: twenty-one-week review: weight, mood, the gastroenteritis, and care while travelling. **S**
